Slide 1: Third Quarter FY 2026 Earnings Results
Third Quarter FY 2026 Earnings Results April 2, 2026
Slide 2: Forward looking statements
Forward looking statements Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: Q3 FY 2026 Key Takeaways
Q3 FY 2026 Key Takeaways Continued commercial and operational execution drives AngioDynamics’ accelerated and profitable growth. Continued Commercial Execution – Q3 FY 2026 YoY Revenue Total Med Tech Med Device Growth* +8.9% +19.0% +1.1% Med Tech YoY Auryon Mech Thrombectomy NanoKnife Probes Revenue
Slide 4: Demonstrated Med Tech Growth Execution
Demonstrated Med Tech Growth Execution Pro Forma Fiscal Year Net Sales ($M) $313.5 - $315.5 $293 $271 $257 Med Tech $235 ~46% of $206 $127 +15% - 17% $186 $96 $106 Total Med Tech $79 $56 ~22% of Total $41 $150 $156 $161 $165 $166 $145 FY20 A FY21 A FY22 A FY23 A FY24 A FY25 A FY26 G* Med Device Med
Slide 5: Q3 FY 2026 Financial Snapshot
Q3 FY 2026 Financial Snapshot Net Sales Segment Revenue Contribution Q3 25 Q3 26 $78.4 $72.0 44% +19.0% 48% $37.3 Pro Forma Growth 56% 52% $31.3 Med Device Med Tech Med Device Med Tech +1.1% Segment Gross Margin Pro Forma Growth $40.7 $41.1 44.2% 62.5% Q3 25 Q3 26 Med Device Med Tech Med Device Med
Slide 6: Med Tech - Auryon
Med Tech - Auryon Combination of Auryon’s best-in-class technology and our commercial strategy have positioned Auryon as a consistently high-growth platform being supported by superior outcomes and ongoing investment to expand applicability Period Sales YoY Growth Q3 FY 2026 $16.3M 17.9% • Continued
Slide 7: Med Tech – Thrombus Management
Med Tech – Thrombus Management Combination of AlphaVac and AngioVac represent a strong, highly competitive mechanical thrombectomy portfolio which continues to take market share driven by expanded joint commercial strategy Q3 FY 2026 Sales YoY Growth AlphaVac $4.4M 47.4% AngioVac $7.2M 5.0% Total Me
Slide 8: Med Tech - NanoKnife
Med Tech - NanoKnife Adoption has continued to accelerate within Prostate as this novel therapy gains traction following receipt of FDA clearance in Dec 2024 Q3 FY 2026 Sales YoY Growth Disposables $5.9M 20.0% Capital $1.7M 24.9% Total $7.6M 21.0% • Continued demand for NanoKnife for prostate drivin
Slide 9: Compelling FY 2026 Financial Outlook
Compelling FY 2026 Financial Outlook supported by balance sheet strength FY 2026 Net Sales ($M) FY 2026 Financial Guidance* $313.5 - $315.5 Current Prior Metric Action $293 Guidance Guidance Net Sales Increased $313.5 - $315.5M $312 - $314M +15 - 17% Med Tech Med Tech Net Sales Growth Increased +15%
Slide 10: Appendix
Appendix 10
Slide 11: Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income Statements
Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income Statements (in thousand, except per share data) 11
Slide 12: Reconciliation of Net Loss to Non-GAAP Adjusted Net Income (Loss) and EPS
Reconciliation of Net Loss to Non-GAAP Reconciliation of Net Loss and non-GAAP Adjusted Net Income (Loss) and EPS and Pro Pro Forma Adjusted Net Loss to Adjusted Forma Adjusted Net Loss and EPS EBITDA and Pro Forma Adjusted EBITDA (in thousands, except per share data) (in thousands) 12
Slide 13: Reconciliation of Net Loss to Non-GAAP Adjusted Net Loss and EPS and Pro Forma
Reconciliation of Net Loss to Non-GAAP Reconciliation of Net Loss and Non-GAAP Adjusted Net Loss and EPS and Pro Forma Pro Forma Adjusted Net Loss to Adjusted Adjusted Net Loss and EPS EBITDA and Pro Forma Adjusted EBITDA (in thousands, except per share data) (in thousands) 13
Slide 14: Detail of “Acquisition, Restructuring and Other Items, net”
Detail of “Acquisition, Restructuring and Other Items, net” (in thousands) 14
Slide 15: Reconciliation of GAAP to Non-GAAP Pro Forma Results for Sales and Gross Margin by Product Category
Reconciliation of GAAP to Non-GAAP Pro Forma Results for Sales and Gross Margin by Product Category (in thousands) 15